Cargando…
Thrombosis and thrombocytopenia after vaccination against and infection with SARS-CoV-2 in Catalonia, Spain
Population-based studies can provide important evidence on the safety of COVID-19 vaccines. Here we compare rates of thrombosis and thrombocytopenia following vaccination against SARS-CoV-2 with the background (expected) rates in the general population. In addition, we compare the rates of the same...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9684434/ https://www.ncbi.nlm.nih.gov/pubmed/36418321 http://dx.doi.org/10.1038/s41467-022-34669-9 |
_version_ | 1784835280366206976 |
---|---|
author | Burn, Edward Roel, Elena Pistillo, Andrea Fernández-Bertolín, Sergio Aragón, Maria Raventós, Berta Reyes, Carlen Verhamme, Katia Rijnbeek, Peter Li, Xintong Strauss, Victoria Y. Prieto-Alhambra, Daniel Duarte-Salles, Talita |
author_facet | Burn, Edward Roel, Elena Pistillo, Andrea Fernández-Bertolín, Sergio Aragón, Maria Raventós, Berta Reyes, Carlen Verhamme, Katia Rijnbeek, Peter Li, Xintong Strauss, Victoria Y. Prieto-Alhambra, Daniel Duarte-Salles, Talita |
author_sort | Burn, Edward |
collection | PubMed |
description | Population-based studies can provide important evidence on the safety of COVID-19 vaccines. Here we compare rates of thrombosis and thrombocytopenia following vaccination against SARS-CoV-2 with the background (expected) rates in the general population. In addition, we compare the rates of the same adverse events among persons infected with SARS-CoV-2 with background rates. Primary care and linked hospital data from Catalonia, Spain informed the study, with participants vaccinated with BNT162b2 or ChAdOx1 (27/12/2020-23/06/2021), COVID-19 cases (01/09/2020-23/06/2021) or present in the database as of 01/01/2017. We included 2,021,366 BNT162b2 (1,327,031 with 2 doses), 592,408 ChAdOx1, 174,556 COVID-19 cases, and 4,573,494 background participants. Standardised incidence ratios for venous thromboembolism were 1.18 (95% CI 1.06-1.32) and 0.92 (0.81-1.05) after first- and second dose BNT162b2, and 0.92 (0.71-1.18) after first dose ChAdOx1. The standardised incidence ratio for venous thromboembolism in COVID-19 was 10.19 (9.43-11.02). Standardised incidence ratios for arterial thromboembolism were 1.02 (0.95-1.09) and 1.04 (0.97-1.12) after first- and second dose BNT162b2, 1.06 (0.91-1.23) after first-dose ChAdOx1 and 4.13 (3.83-4.45) for COVID-19. Standardised incidence ratios for thrombocytopenia were 1.49 (1.43-1.54) and 1.40 (1.35-1.45) after first- and second dose BNT162b2, 1.28 (1.19-1.38) after first-dose ChAdOx1 and 4.59 (4.41- 4.77) for COVID-19. While rates of thrombosis with thrombocytopenia were generally similar to background rates, the standardised incidence ratio for pulmonary embolism with thrombocytopenia after first-dose BNT162b2 was 1.70 (1.11-2.61). These findings suggest that the safety profiles of BNT162b2 and ChAdOx1 are similar, with rates of adverse events seen after vaccination typically similar to background rates. Meanwhile, rates of adverse events are much increased for COVID-19 cases further underlining the importance of vaccination. |
format | Online Article Text |
id | pubmed-9684434 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-96844342022-11-25 Thrombosis and thrombocytopenia after vaccination against and infection with SARS-CoV-2 in Catalonia, Spain Burn, Edward Roel, Elena Pistillo, Andrea Fernández-Bertolín, Sergio Aragón, Maria Raventós, Berta Reyes, Carlen Verhamme, Katia Rijnbeek, Peter Li, Xintong Strauss, Victoria Y. Prieto-Alhambra, Daniel Duarte-Salles, Talita Nat Commun Article Population-based studies can provide important evidence on the safety of COVID-19 vaccines. Here we compare rates of thrombosis and thrombocytopenia following vaccination against SARS-CoV-2 with the background (expected) rates in the general population. In addition, we compare the rates of the same adverse events among persons infected with SARS-CoV-2 with background rates. Primary care and linked hospital data from Catalonia, Spain informed the study, with participants vaccinated with BNT162b2 or ChAdOx1 (27/12/2020-23/06/2021), COVID-19 cases (01/09/2020-23/06/2021) or present in the database as of 01/01/2017. We included 2,021,366 BNT162b2 (1,327,031 with 2 doses), 592,408 ChAdOx1, 174,556 COVID-19 cases, and 4,573,494 background participants. Standardised incidence ratios for venous thromboembolism were 1.18 (95% CI 1.06-1.32) and 0.92 (0.81-1.05) after first- and second dose BNT162b2, and 0.92 (0.71-1.18) after first dose ChAdOx1. The standardised incidence ratio for venous thromboembolism in COVID-19 was 10.19 (9.43-11.02). Standardised incidence ratios for arterial thromboembolism were 1.02 (0.95-1.09) and 1.04 (0.97-1.12) after first- and second dose BNT162b2, 1.06 (0.91-1.23) after first-dose ChAdOx1 and 4.13 (3.83-4.45) for COVID-19. Standardised incidence ratios for thrombocytopenia were 1.49 (1.43-1.54) and 1.40 (1.35-1.45) after first- and second dose BNT162b2, 1.28 (1.19-1.38) after first-dose ChAdOx1 and 4.59 (4.41- 4.77) for COVID-19. While rates of thrombosis with thrombocytopenia were generally similar to background rates, the standardised incidence ratio for pulmonary embolism with thrombocytopenia after first-dose BNT162b2 was 1.70 (1.11-2.61). These findings suggest that the safety profiles of BNT162b2 and ChAdOx1 are similar, with rates of adverse events seen after vaccination typically similar to background rates. Meanwhile, rates of adverse events are much increased for COVID-19 cases further underlining the importance of vaccination. Nature Publishing Group UK 2022-11-23 /pmc/articles/PMC9684434/ /pubmed/36418321 http://dx.doi.org/10.1038/s41467-022-34669-9 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Article Burn, Edward Roel, Elena Pistillo, Andrea Fernández-Bertolín, Sergio Aragón, Maria Raventós, Berta Reyes, Carlen Verhamme, Katia Rijnbeek, Peter Li, Xintong Strauss, Victoria Y. Prieto-Alhambra, Daniel Duarte-Salles, Talita Thrombosis and thrombocytopenia after vaccination against and infection with SARS-CoV-2 in Catalonia, Spain |
title | Thrombosis and thrombocytopenia after vaccination against and infection with SARS-CoV-2 in Catalonia, Spain |
title_full | Thrombosis and thrombocytopenia after vaccination against and infection with SARS-CoV-2 in Catalonia, Spain |
title_fullStr | Thrombosis and thrombocytopenia after vaccination against and infection with SARS-CoV-2 in Catalonia, Spain |
title_full_unstemmed | Thrombosis and thrombocytopenia after vaccination against and infection with SARS-CoV-2 in Catalonia, Spain |
title_short | Thrombosis and thrombocytopenia after vaccination against and infection with SARS-CoV-2 in Catalonia, Spain |
title_sort | thrombosis and thrombocytopenia after vaccination against and infection with sars-cov-2 in catalonia, spain |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9684434/ https://www.ncbi.nlm.nih.gov/pubmed/36418321 http://dx.doi.org/10.1038/s41467-022-34669-9 |
work_keys_str_mv | AT burnedward thrombosisandthrombocytopeniaaftervaccinationagainstandinfectionwithsarscov2incataloniaspain AT roelelena thrombosisandthrombocytopeniaaftervaccinationagainstandinfectionwithsarscov2incataloniaspain AT pistilloandrea thrombosisandthrombocytopeniaaftervaccinationagainstandinfectionwithsarscov2incataloniaspain AT fernandezbertolinsergio thrombosisandthrombocytopeniaaftervaccinationagainstandinfectionwithsarscov2incataloniaspain AT aragonmaria thrombosisandthrombocytopeniaaftervaccinationagainstandinfectionwithsarscov2incataloniaspain AT raventosberta thrombosisandthrombocytopeniaaftervaccinationagainstandinfectionwithsarscov2incataloniaspain AT reyescarlen thrombosisandthrombocytopeniaaftervaccinationagainstandinfectionwithsarscov2incataloniaspain AT verhammekatia thrombosisandthrombocytopeniaaftervaccinationagainstandinfectionwithsarscov2incataloniaspain AT rijnbeekpeter thrombosisandthrombocytopeniaaftervaccinationagainstandinfectionwithsarscov2incataloniaspain AT lixintong thrombosisandthrombocytopeniaaftervaccinationagainstandinfectionwithsarscov2incataloniaspain AT straussvictoriay thrombosisandthrombocytopeniaaftervaccinationagainstandinfectionwithsarscov2incataloniaspain AT prietoalhambradaniel thrombosisandthrombocytopeniaaftervaccinationagainstandinfectionwithsarscov2incataloniaspain AT duartesallestalita thrombosisandthrombocytopeniaaftervaccinationagainstandinfectionwithsarscov2incataloniaspain |